Financials data is unavailable for this security.
View more
Year on year Beijing Tong Ren Tang Chinese Medicine Co Ltd 's revenues fell -11.91% from 1.73bn to 1.52bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 645.88m to 540.39m, a -16.33% decrease.
| Gross margin | 72.06% |
|---|---|
| Net profit margin | 38.72% |
| Operating margin | 40.17% |
| Return on assets | 12.72% |
|---|---|
| Return on equity | 13.37% |
| Return on investment | 14.09% |
More ▼
Cash flow in HKDView more
In 2023, cash reserves at Beijing Tong Ren Tang Chinese Medicine Co Ltd fell by 991.15m. However, the company earned 460.83m from its operations for a Cash Flow Margin of 30.22%. In addition the company used 1.08bn on investing activities and also paid 372.18m in financing cash flows.
| Cash flow per share | 0.7386 |
|---|---|
| Price/Cash flow per share | 10.18 |
| Book value per share | 4.55 |
|---|---|
| Tangible book value per share | 4.48 |
More ▼
Balance sheet in HKDView more
| Current ratio | 16.79 |
|---|---|
| Quick ratio | 9.55 |
| Total debt/total equity | 0.0352 |
|---|---|
| Total debt/total capital | 0.0327 |
More ▼
Growth rates in HKD
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -16.33%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.52% |
|---|---|
| Div growth rate (5 year) | 7.49% |
| Payout ratio (TTM) | 55.90% |
| EPS growth(5 years) | -1.43 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -29.13 |
More ▼
